"Neuroscience at the New Millennium" presents the strategic plan for the National Institute of Neurological Disorders and Stroke (NINDS). This supplement describes the actions NINDS is taking to implement our strategic plan. Because planning is a dynamic process that is integral to the operation of the Institute, this document can only offer a snapshot of activities as of May 2000.
The planning process began in the fall of 1998. Following consultation with the National Advisory Neurological Disorders and Stroke Council, NINDS convened leaders from the scientific community, together with patient advocates and NINDS staff, to assess needs, opportunities, and priorities in several cross-cutting scientific areas. The seven panels focused on Neurodegeneration; Neurogenetics; Channels, Synapses and Circuits; Cognition and Behavior; Neurodevelopment; Plasticity and Repair; Glia and Other Non-Neuronal Cells; and Experimental Therapeutics and Clinical Trials. The panel reports shaped the first draft of the NINDS strategic plan. NINDS posted the draft on the internet and solicited comments from more than 250 patient advocacy groups and professional scientific organizations. The NINDS director and staff continue to meet with these groups, and the Institute is actively engaged in efforts to enhance its partnership with private organizations. Meetings of the planning panels are also continuing, both to discuss specific implementation proposals and to consider new opportunities and issues arising within the rapidly changing landscape of neuroscience research. As the planning process continues, NINDS will present new iterations of the strategic plan at regular intervals.
In order to more effectively carry out its mission, NINDS has reorganized its extramural staffing. The new structure groups program directors into clusters that reflect the themes around which the planning process coalesced. All diseases clearly cross cluster boundaries. Individual program directors will maintain a focus on particular diseases within this structure, while the cluster themes foster cross fertilization that has become central to progress against all disorders. The more level organizational structure promotes staff initiative and communication. New positions are spearheading important cross-cutting efforts in technology development, clinical trials and experimental therapeutics. NINDS is also undertaking extensive efforts to recruit high caliber scientist-administrators to guide these efforts, with several new program directors already in place to replace retirees and to fill new positions.
NINDS has always relied heavily on the insight and ingenuity of scientists throughout the country to identify research needs and opportunities. The Institute continues its emphasis on investigator initiated research with the strong endorsement of the NINDS Advisory Council and of the planning panels. In FY1999, the success rate for new and competing centers and research project grants rose to over 35%, and NINDS funded more than 400 new grants for a total portfolio of about 2,200 projects. Importantly, every indication is that the high scientific quality of these grants is not diminished. The excitement of neuroscience is drawing many established scientists, graduate students and post-doctoral students to the frontiers of brain research, but the Institute must be vigilant to maintain a talented scientific workforce and a balanced program.
While NINDS relies heavily on investigator initiated research, the Institute undertakes specific initiatives to focus efforts on particular problems or opportunities when Institute leadership is warranted. The current favorable funding environment has enabled NINDS to aggressively seek to catalyze progress, while maintaining the success rates sufficient to sustain the health of the scientific enterprise. The specific initiatives described in the following sections, together with the increase in new grants, would not be possible in more constrained fiscal circumstances.
While we are implementing all areas of our strategic plan (see remainder of this supplement), a few examples will illustrate the range of activities NINDS is undertaking to carry out the plan.
Recent advances in understanding the causes of Parkinson's disease, and the possibility of new treatment options, has brought a renewed sense of optimism that Parkinson's disease can be cured, or treated more effectively, in the not too distant future. In late 1999, NINDS, together with several other NIH Institutes and patient advocacy groups, initiated an intensive planning process to develop a research agenda for Parkinson's disease. A workshop was held this past January at which intramural, extramural and industry scientists, together with patient advocates and ethicists, identified opportunities for moving the field forward towards a cure. In March, a five year plan based on the workshop recommendations was published, and NINDS is currently working to implement this plan. Already, several solicitations for research proposals have been issued, including ones on the role of parkin and related proteins in Parkinson's disease, mitochondrial function and neurodegeneration, and the function of synaptic proteins in synapse loss and neurodegeneration. In addition, NINDS has established 11 Morris K. Udall Centers of Excellence in Parkinson's Disease research. These centers meet regularly to coordinate activities, and will be critical to fostering the type of cross disciplinary efforts needed to implement the plan. It is important to note that while the research agenda is focused on Parkinson's disease, the knowledge gained from it will have relevance for all forms of neurodegenerative disease.
The scientific community has responded enthusiastically to an NINDS solicitation for research on deep brain stimulation. Proposals range from technology development through clinical trials for Parkinson's disease. Deep brain stimulation is a potentially revolutionary therapeutic approach that may apply to many brain disorders in addition to Parkinson's Disease.
This past March, NINDS, together with several patient advocacy groups, sponsored a White House-initiated conference, "Curing Epilepsy: Focus on the Future." This conference brought together leading scientists with representatives from government, industry, healthcare organizations, and patient groups, to discuss research advances and stimulate creative thinking as to what exciting and innovative discoveries are likely to lead to the prevention and cure of epilepsy. Cure is defined as "the prevention of epilepsy before it occurs in people at risk, and the cessation of seizures and other symptoms without therapy-associated side effects in those who develop the disease." Major topics for discussion included interrupting seizure development, using genetic strategies, and developing new therapies. NINDS is currently convening a planning group to develop a 5 year research agenda based on the recommendations that came out of the conference.
In order to encourage new approaches to curing epilepsy, NINDS, together with the Epilepsy Foundation and the American Epilepsy Society, awarded 48 travel supplements for young investigators to attend the White House conference and learn about a new NINDS initiative for Exploratory/Developmental Grants for "Innovation in Translational Epilepsy Research for Junior Investigators." The purpose of this initiative is to bring together promising junior investigators with interest in patient-oriented research, developmental neurobiology, genetics, advanced technology, imaging, pharmacotherapeutics, and other disciplines to develop innovative research proposals related to the field of epilepsy.
NINDS has developed and is implementing a five year strategic plan to reduce the burdens borne by populations at increased risk for diseases and disorders of the brain, spinal cord, and peripheral nervous system. Minority populations are typically at greater risk for stroke, epilepsy, neurological complications of AIDS and diabetes, traumatic brain/spinal cord injury, and developmental disorders, including those associated with low birthweight. Progress against these disorders will be greatly enhanced by the existence of a strong cadre of minority investigators and institutions who are fully engaged in research and health care. In collaboration with other NIH Institutes and Centers, NINDS is cooperating with minority medical and graduate schools to develop state-of-the-art basic and clinical neuroscience programs, including sustainable, replicable and culturally appropriate prevention and/or intervention programs in areas such as stroke and HIV/AIDS.
In FY1999 NINDS offered an innovative program of supplements targeted to support critical infrastructure needs. The Institute invited current grantees to apply, with a brief application and rapid turn-around, for needed equipment costing up to $50,000 for single investigators or $200,000 for groups. The overwhelming response rate, from more than 90% of grantees, and the quality of the justifications presented, highlight the unmet needs that have accumulated in laboratories following many years of budgetary constraints. The NINDS Advisory Council and the Planning Panels have strongly endorsed this program as a cost-effective means to ensure that research is not hampered by the lack of equipment essential to day-to-day research efforts. NINDS plans to continue this program of infrastructure supplements in FY2000.
Almost half of all human genes are expressed in the brain. Understanding the differential expression of these genes will greatly increase our understanding of both normal brain function and neurological disease. To facilitate this effort, NINDS has recently announced a program of supplements to increase access to DNA microarray technology. Increased access to microarrays was a major recommendation of almost all of the Planning Panels. This effort, modeled on the highly successful general infrastructure supplement program (see above), will provide funds for the use and analysis of DNA microarrays of up to $50,000 for single investigators or $100,000 for program projects. In addition, NINDS is developing an initiative for microarray centers for research on the nervous system. These centers would provide a source of neuroscience-specific, quality-controlled microarrays, and a range of services to facilitate access to the use of arrays for NINDS grantees.
About 200,000 Americans are confined to wheelchairs because of spinal cord injury (SCI). Each year, more than 10,000 new serious spinal cord injuries occur, with two-thirds of the victims being under the age of 30. NINDS has recently initiated a series of small, focused, multidisciplinary workshops to review recent research advances, explore new mechanisms, and develop novel strategies for the treatment of different aspects of acute and chronic SCI. Each workshop brings together SCI scientists, experts in related or relevant fields, and patient advocates to focus on a specific topic in the recovery process. Topics will include inflammation and cell responses following SCI, barriers to regeneration in SCI, synapse formation and plasticity in regenerating systems, cell and gene therapy in the damaged spinal cord, the role of rehabilitation and neural prostheses, and the development of improved imaging and clinical outcome measures for SCI. The first workshop in the series was held this past April, and others are planned on a regular basis over the next year and a half.
The NIH intramural program provides unique opportunities for interdisciplinary collaborations, for long-term studies, and for rapid response to problems of special urgency. The unique advantages of the NIH Clinical Center for clinical research are becoming even more valuable in today's health care environment. The NIH intramural neuroscience program is well on its way towards regaining its position of world leadership in quality and in integration of the many scientific perspectives that must be brought to bear on problems of the brain. Efforts spearheaded by NINDS and NIMH Scientific Directors have recruited outstanding scientists, at senior and junior levels, and the entire enterprise has prospered under new procedures for recruitment and tenure of independent investigators. Funding for a new Neuroscience Center has been included in the President's FY2001 budget, which when built will at last provide an environment conducive to modern integrated neuroscience research.
NINDS was instrumental in the development of tPA (tissue plasminogen activator), the first FDA approved acute treatment for ischemic stroke. Now that emergency treatment for stroke has been proven possible, NINDS will continue to build on this success with expanded efforts to educate the public and health care providers about new stroke treatment opportunities and by continuing research to develop better treatments. As part of this effort the NINDS Intramural program is collaborating with NHLBI and Suburban Hospital (a local community hospital) to form a comprehensive multidisciplinary stroke care program. Doctors at Suburban will use the latest MRI imaging technology to rapidly diagnose individuals presented with ischemic stroke so that tPA treatment can be begun immediately. Researchers will utilize the MRI technology in clinical trials aimed at identifying and evaluating new therapies that permanently reduce the brain damage caused by stroke.
The NINDS is working together with the National Cancer Institute (NCI) to support basic, clinical, and population-based research to identify and study the causes, biology, prevention, early detection and treatment of brain tumors. Years of research support have resulted in a large knowledge base about neoplastic disease that, together with new technologies, presents a wealth of exciting scientific opportunities. In order to best exploit these opportunities, the NINDS and NCI have organized a Progress Review Group (PRG) for brain tumor research. This joint PRG, modeled on NCI's PRG efforts in other cancer areas, will identify scientific priority areas in brain tumor research, provide a framework to determine whether existing initiatives address these priority areas, and galvanize the research community to undertake projects in the identified priority areas.
Our implementation efforts are not taking place in a vacuum. Rather, they must be integrated within the larger strategic planning effort taking place across the NIH campus. Many of our current and planned initiatives cross disciplinary boundaries, and we will make every effort to collaborate with other NIH Institutes and Centers in areas of common interest. We continue to participate in several important NIH-wide activities, including human, rat, mouse, and zebrafish genomic projects. In addition, we either lead or participate with our fellow Institutes on several trans-NIH coordinating committees including the NIH Pain Research Consortium; the Parkinson's Disease Coordinating Committee; the Alzheimer's Disease Coordinating Committee; the NIH Autism Coordinating Committee; the Autoimmunity Coordinating Committee; the NIH Bioengineering Consortium; the NIH Biomedical Information Science and Technology Initiative; the NIH Consensus Conference and Technology Transfer Coordinating Committee; and other committees covering prevention, behavioral and social sciences research. Finally, our program directors interact on a daily basis with their colleagues at other NIH Institutes in areas of common interest to ensure that our collective resources are utilized productively.
The remainder of this document is organized around the topic areas contained in the accompanying strategic plan. Listed within each section are current initiatives, planned initiatives, and scientific workshops and conferences either recently held or planned for the coming year. Several of these efforts, as indicated, are cooperative efforts led by other components of NIH. In addition, an appendix lists all our current initiatives in date order for easy reference, along with specific reference numbers that will allow access to more complete information via the internet.
NINDS encourages research into neurodegeneration over the entire life span.
Examples of disease areas covered include Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Friedreich's Ataxia, the spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), and stroke.
NINDS plans and implements research on normal and abnormal neurodevelopment, disorders of the developing nervous system, and developmental processes whose dysfunction may lead to neurological disease in adulthood.
Examples of diseases covered include developmental disorders such as autism, Rett syndrome, Tourette syndrome, cerebral palsy and Down syndrome; malformations of brain and spinal cord; epilepsy; spinal muscular atrophy (SMA) and other childhood neurodegenerative disorders; the muscular dystrophies; Batten disease and other metabolic disorders (e.g., Tay-Sachs disease, Fabry's disease, Gaucher's disease, other storage diseases); Reye's syndrome; aminoacidurias; ataxia telangiectasia; and Friedreich's ataxia.
NINDS plans and directs research on interventions to restore function in the damaged nervous system and conducts basic research on neural plasticity as it relates to repair following degenerative diseases, injury, and stroke.
Examples of disease areas covered include traumatic brain and spinal cord injury, stroke, and repair and plasticity aspects of neurodegenerative disorders.
NINDS facilitates research to increase our knowledge of glia, cerebrovascular and immune cells, and infectious agents in the healthy and diseased system.
Examples of disease areas include stroke and vascular diseases, tumors (glioblastomas, meningiomas, neurofibromas), infections (meningitis, poliomyelitis and its sequelae, neuro-AIDs, Lyme disease), autoimmune disorders (multiple sclerosis, myasthenia gravis, Guillain-Barre syndrome, CIDP, paraneoplastic syndromes), and polymyositis.
NINDS plans and implements research in the neurobiology of higher cognitive functions and other complex behaviors.
Examples of disease areas include pain, developmental learning disabilities, autism, dementia, movement disorders, dystonias, sleep disorders (narcolepsy, restless leg syndrome) and peripheral neuropathies.
NINDS initiates and promotes basic, translational, and clinical research in channels, synapses, and neural circuits that underlie normal brain functions and dysfunctions related to neurological disorders such as epilepsy.
Examples of diseases covered include epilepsy, pain, and the various disorders of ion channels, including several forms of ataxia, seizure disorders, and neuromuscular diseases.
Promoting clinical research is a major priority for NINDS. Prior to the development of the strategic plan, the Institute formed a working group to monitor progress and propose new mechanisms and initiatives. A new position of Associate Director for Clinical Trials provides a focus for these efforts, and recruitment of a new Clinical Director for the intramural research program will provide further stimulus for NINDS to lead the way in translational research, experimental therapeutics, and clinical trials.
NINDS supports and encourages research on a variety of topics in neurogenetics, ranging from gene discovery and intervention studies in specific diseases to NIH-wide genomics efforts.
Throughout the strategic planning process, NINDS staff and advisors have noted the critical importance of providing sufficient manpower, technology, and infrastructure to support modern neuroscience research and to compensate for the effects of past funding constraints. In addition to the specific initiatives and plans noted below, the Institute has created a new position of Associate Director for Technology Development to provide leadership in many of these efforts.
(all in collaboration with one or several ICs)
The NINDS Intramural program has recruited leading senior neuroscientists to spearhead enhanced efforts in neurogenetic diseases, brain imaging, and stroke treatment. The Institute has also hired some of the nation's best young scientists studying the development of the nervous system, the structure and function of ion channels, and the molecular biology of synapses. The Institute is continuing efforts to enhance the Intramural Clinical programs, to hire a new clinical director, to enhance collaborations with other ICs, and to provide laboratory space that will promote collaborative approaches to neuroscience research on the NIH campus. Ongoing and planned intramural clinical trials cover a broad spectrum of rare and common neurological disorders.
(See http://grants.nih.gov/grants/funding/funding.htm for full text of these and new initiatives)
Recent and Ongoing NINDS Led Initiatives
NINDS Administrative Supplements for DNA Microarray Analysis
The Role of Parkin and Related Proteins in Parkinson's Disease
Innovations in Translational Epilepsy Research for Junior Investigators
Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis, and other Motor Neuron Disorders
Mitochondrial Function and Neurodegeneration
The Function of Synaptic Proteins in Synapse Loss and Neurodegeneration
Pilot Studies for Re-establishing Connectivity in Spinal Cord Injury
Biomaterials for the Central Nervous System
Mechanisms in HIV Dementia and other CNS Diseases
The Restoration of Hand and Arm Function by Functional Neuromuscular Stimulation
Neurobiology of Diabetic Complications
Analysis of Gene Expression Patterns in the Nervous System
The Role of Microglia in Normal and Abnormal Immune Responses of the Nervous System
Biomaterials for the Microelectrode Neural Interface
Thin-Film Intracortical Recording Microelectrodes
Consortium on Deep Brain Stimulation for the Treatment of Parkinson's Disease and Other Neurological Disorders
Interneuronal Circuits Underlying Voluntary Movements in Normal and Injured Spinal Cord
Specialized Neuroscience Research Programs at Minority Institutions
Specialized Neuroscience Research Program on Health Disparity: HIV and the Nervous System
High Throughput Analysis of Gene Expression Patterns in the Nervous System
Exploratory Grants in Pediatric Brain Disorders: Integrating the Sciences
Development of Assay for Creutzfeldt-Jakob Disease
Neurological Complications of Diabetes
Morris K. Udall Parkinson's Disease Research Centers of Excellence
Cortical Control of Neural Prostheses
Technologies for Gene Expression Analysis In The Nervous System
Central Nervous System as the HIV Sanctuary
PHS SBIR Contract
Neuroimaging in HIV Infection
Micromachined Stimulating Microelectrode Arrays
Animal Care and Housing Support Services for Study of Slow, Latent and Temperate Virus Infections of the Nervous System Caused by Conventional and Unconventional Viruses; and; Maintenance of a Breeding Colony of Rhesus Monkeys for Intramural Research
Pediatric Anatomic Neuroimaging Data Base Initiative
Development of Virtual Reality Headgear/Gloves for Use in Administration of Cognitive and Motor Tasks
NINDS Clinical Trial Planning Grant
Pilot Clinical Trial Grant for Neurological Disease
The Early Evaluation of Anticonvulsant Drugs
Recent and Ongoing Initiatives Led by Other Institutes/Centers
Earth-bases Research Relevant to the Space Environment - 10 ICs, NASA
Mutagenesis Screens/ Phenotyping Tools for Zebrafish - 16 ICs
Rett Syndrome: Genetics, Pathophysiology, and Biomarkers - NICHD, with NINDS
Mechanisms of HIV-1 Trafficking in the CNS - NIMH, with NINDS
Transitional Career Development Award in Women's Health Research - ORWH with 15 other IC's
Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences - 9 ICs
Developmental Pharmacology: Ontogeny of Drug Metabolizing Enzymes, Drug Transporters, Drug Receptors, and Ion Channels - NICHD, with NIDA, NINDS
Impact of HAART on HIV/CNS Disease-NIMH, with NINDS
Bioengineering Nanotechnology Initiative - NCI with 18 other ICs
Mentored Research Scientist Development Award-14 ICs
Independent Scientist Award-14 ICs
Bioengineering Research Partnerships-NCI with 18 other ICs
Hyperaccelerated Award/Mechanisms in Immunomodulation Trials-NIAID with 6 other ICs
Gene Expression Profiling in the Nervous System- NIMH with 6 other ICs
Mentored Clinical Scientist Development Award- 17 ICs included
Mentored Patient-Oriented Research Career Development Award-17 ICs included
Midcareer Investigator Award in Patient-Oriented Research-17 ICs included
The Role of the Environment in Parkinson's Disease-NIEHS, with NINDS
The Role of the Environment in Parkinson's Disease: Career Development Programs for Physician-Scientists-NIEHS, with NINDS
Building Interdisciplinary Research Careers in Women's Health-ORWH with 12 ICs and AHCPR
The Role of Growth Factors in the Development of Diabetes Complications-NIDDK with 4 other ICs
Career Development Awards: Child Abuse and Neglect Research-NIMH with 4 other ICs
The Human Brain Project (Neuroinformatics): Phase I & Phase II)-NIMH with 11 other ICs, NSF, DOE and NASA
The Aging Senses: Relationships Among Multiple Sensory Systems: NIA with 5 other ICs
SBIR/STTR Study and Control of Microbial Biofilms-NHLBI with 10 other ICs
Clinical Interventions for Managing the Symptoms of Stroke-NINR with 4 other ICs
Thrombosis of the Arterial and Cerebral Vasculature: New Molecular Genetic Concepts for Prevention and Treatment-NHLBI
Thrombosis of the Arterial and Cerebral Vasculature: New Molecular Genetic Concepts for Prevention and Treatment-NHLBI
Mentored Quantitative Research Career Development Award-NHLBI with 14 other ICs
Research on Ethical Issues in Human Studies-NCI with 20 other ICs
Mouse Mutagenesis and Phenotyping: Nervous System and Behavior-NIMH with 6 other ICs
Research on Child Neglect-OBSSR with 4 other ICs
Technologies For Generation of Full-Length Mammalian cDNA-NCI with 15 other ICs
Rat Genome Database-NHLBI with 10 other ICs
Target Organ Damage in Autoimmune Disease- NIAMS with 11 other ICs
Neuroimaging Analyses as Correlates of HIV/CNS Disease-NIMH
Academic Research Enhancement Award-NCI with 20 other ICs
New Imaging Techniques for Autoimmune Diseases-NIAID with 10 other ICs
Environment/Infection/Gene Interactions in Autoimmune Disease-NIEHS with 11 other ICs
Xenobiotics and Cell Death/Injury in Neurodegenerative Disease-NIEHS, with NIMH, NIA, NINDS
HIV Co-receptors in the CNS-NIDA, with NIMH, NINDS
Non-Human Primate Models for HIV/CNS Disease- NIMH, with NINDS
Phenotyping the Mouse Nervous System and Behavior-NIMH with 6 other ICs
Centers for Mind/Body Interactions and Health -OBSSR with 12 other ICs
Research on Care at the End of Life-NINR with 8 other ICs
Alzheimer's Disease Clinical Trial Planning Grant-NIA with NIMH, NINDS
Alzheimer's Disease Pilot Clinical Trials-NIA with NIMH, NINDS
Rett Syndrome: Genetics, Pathophysiology and Biomarkers-NICHD
Phenotypic Characterization of Sleep in Mice-NHLBI with 3 other ICs
Research on Tissue Engineering-NIAMS with 10 other ICs
Biobehavioral Pain Research-NINR with 10 other ICs
Bioengineering Research Grants-NCI with 19 other ICs
Structural Biology of Membrane Proteins-NIGMS with 5 other ICs
Child Abuse and Neglect
Deep Brain Stimulation for Parkinson's Disease Working Group
Parkinson's Disease Center Investigator's Meeting
Progressive Supranuclear Palsy International Meeting
Future Genetic Strategies for Epilepsy
Batten Disease Workshop: New Directions in Research for the Neuronal Ceroid Lipofuscinoses
HIV and the Nervous System
Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications
Spinal Muscular Atrophy Workshop
NIRS as a Cerebral Function Monitor
Glioma Cell Biology Workshop
International Freidreich's Ataxia Conference
Pediatric Functional Neuroimaging Workshop
International Sturge-Weber Syndrome Symposium
Neural Stem Cells: Promoting Repair and Plasticity of the Nervous System
International Conference on Batten Disease
Phantom Limb Pain
Trigeminal Neuralgia: Opportunities for Research and Treatment
Workshop on Optical Imaging
Inter-Institute Invitational Conference on Coordinating Neuroimaging and Functional Paradigms for Understanding Pediatric Neurodevelopment
30th Annual Neural Prostheses Workshop
Pelizaeus/Merzbeher Disease and the allelic Disorder, X-linked Spastic Paralpegia Type 2
Neiman Pick Type C Disease Symposium
Symposium on Neural Plasticity: New Insights into Persistent Pain States (as part of the Pain Society meeting)
NIH and NSF Funding and Research Opportunities (at Society for Neuroscience Meeting)
The Role of MRI as the Surrogate Outcome Measure for Multiple Sclerosis
Treatments for People with Autistic and Other Pervasive Developmental Disorders: Research Perspectives
The Dopamine Connections in Restless Legs Syndrome, Periodic Limb Movement Disorder, Parkinsonism and Narcolepsy: Toward a Better Understanding of Common Mechanisms in Uncommon Disorders
Adaptive Learning: Interventions for Verbal and Motor Deficits
Neuronal Ceroid Lipofuscinoses Research Association Actions for Therapy Workshop
Neuro-AIDS Technical Assistance Workshop: Specialized Neuroscience Research Programs
Neurobiology of Ataxia-Teleangiectasia (A-T)
Clinical Trial Design for Antiepileptogenic vs. Antiepileptic Agents (at American Epilepsy Society 1999 Annual Meeting)
Parkinson's Disease Research Agenda: Progress and Five Year Plan
Technology Assessment Conference on Improving Medical Implant Performance through Retrieval Information
Workshop on HTLV-1
Parkinson's Disease Center Investigator's Meeting
Symposium on Hereditary Spastic Paraplegias
Genetic Basis for Brain Development and Dysfunction
White House Conference on "Curing Epilepsy: Focus on the Future"
Brain Fatty Acid Uptake, Utilization, and Relevance to PBDS
Roundtable for Progress Review Group on Brain Tumors
Assays for High-Throughput Screening of Therapeutic Drug Candidates for Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA)
Mini-Series on Spinal Cord Injury: Damage Control - Inflammation and cell response following spinal cord injury
Computational and Theoretical Neuroscience: From Synapse to Circuitry
Research Opportunities on Inflammatory Myopathies
NIMH and NINDS Joint Workshop on Neuroimaging Informatics
Defining the Future of Neurofibromatosis Research
Batten Disease: Gene Therapy Initiative Conference
Duchenne Muscular Dystrophy Workshop
Hallovorden-Spatz Syndrome Workshop
Traumatic Brain Injury: Acute Treatment/Long term Outcome
Impact of HAART on HIV-induced Disease of the Nervous System
BECON Conference on Nanotechnology
6th International Conference on Functional Mapping of the Human Brain: Functional Imaging in Development
Mini-Series on Spinal Cord Injury: Functional and dysfunctional spinal circuitry - Role of rehabilitation and neural prostheses
Cerebral Blood Flow and Development and Dysfunction
The Human Brain Project/Informatics Annual Meeting
Post-Resuscitation and Initial Utility in Life Saving Efforts (PULSE)
Roundtable for Progress Review Group on Brain Tumors
Mini-Series on Spinal Cord Injury: To sprout or not to sprout - scars, cysts, inhibitory factors and other barriers to regeneration in spinal cord injury
Pain After Spinal Cord Injury: Maladaptive Plasticity
Pediatric Stroke: Development of Strategies for Prevention and Management
International Scientific Conference on the Spinal Cord in Health and Disease
HIV and the Peripheral Nervous System
Gene Therapy in the Nervous System
Optical Imaging: Bench to Bedside
International Workshop on Diagnostics for Transmissible Spongiform Encephalopathy (TSE) Agents
31st Annual Neural Prostheses Workshops
International Symposium on Myoclonus, Paroxysmal Dyskinesias, and Related Disorders
NIH and NSF Funding and Research Opportunities (at Society for Neuroscience Meeting)
International Workshop on Blepharospasm
Mini-Series on Spinal Cord Injury: Synapse formation and plasticity in regenerating systems
Mini-Series on Spinal Cord Injury: Cell therapy and gene therapy in the damaged spinal cord
Mini-Series on Spinal Cord Injury: Clinical applications - Development of improved outcome measures; Imaging changes in the CNS following spinal cord injury
Stroke Genetics Workshop
Cognitive and Emotional Health Longitudinal Study Meeting
Protein Fingerprinting of Neurodegenerative Diseases
Protein Microassays in Brain and Nervous Tissue
Pain and Epilepsy: Common Drugs, Common Mechanisms
Glioma Cell Biology
New Directions in Pain Research II
National Symposium on Outcomes in Clinical Neurological Research
Developing Quantitative Tools for Assessment of Movement Impairment in Children
Risk Factors for Autism
Channelopathy: Abnormality of Channel Function Underlying Neurological Disease States
Reviewed July 1, 2001
Last Modified October 18, 2015